Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Isogenic patient-derived organoids reveal early neurodevelopmental defects in spinal muscular atrophy initiation. | Cell Rep Med | 2024 | 39067446 | PubTator, text mining | PubMed |
| A Five-Year Review of Newborn Screening for Spinal Muscular Atrophy in the State of Utah: Lessons Learned. | Int J Neonatal Screen | 2024 | 39051410 | PubTator, text mining | PubMed |
| Complex SMN Hybrids Detected in a Cohort of 31 Patients With Spinal Muscular Atrophy. | Neurol Genet | 2024 | 39035824 | PubTator, text mining | PubMed |
| Improvement of TaC9-ABE mediated correction of human SMN2 gene. | Biotechnol Bioeng | 2024 | 38923503 | PubTator, text mining | PubMed |
| Scoliosis Development in Spinal Muscular Atrophy: The Influences of Genetic Severity, Functional Level, and Disease-Modifying Treatments. | J Pediatr Orthop | 2024 | 38916214 | PubTator, text mining | PubMed |
| Truncated variants of MAGEL2 are involved in the etiologies of the Schaaf-Yang and Prader-Willi syndromes. | Am J Hum Genet | 2024 | 38908375 | PubTator, text mining | PubMed |
| Revealing the potential role of hsa-miR-663a in modulating the PI3K-Akt signaling pathway via miRNA microarray in spinal muscular atrophy patient fibroblast-derived iPSCs. | J Neuropathol Exp Neurol | 2024 | 38894621 | PubTator, text mining | PubMed |
| Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA. | Molecules | 2024 | 38893532 | PubTator, text mining | PubMed |
| [Experience with the use of risdiplam in a familial case of spinal muscular atrophy 5q in patients with a homozygous deletion of the SMN1 gene and the same copy number of the SMN2 gene]. | Zh Nevrol Psikhiatr Im S S Korsakova | 2024 | 38884441 | PubTator, text mining | PubMed |
| Spinal muscular atrophy genetic epidemiology and the case for premarital genomic screening in Arab populations. | Commun Med (Lond) | 2024 | 38879606 | PubTator, text mining | PubMed |
| 2024 update: European consensus statement on gene therapy for spinal muscular atrophy. | Eur J Paediatr Neurol | 2024 | 38878702 | PubTator, text mining | PubMed |
| Analytical validation of the amplification refractory mutation system polymerase chain reaction-capillary electrophoresis assay to diagnose spinal muscular atrophy. | Clin Chem Lab Med | 2024 | 38860968 | PubTator, text mining | PubMed |
| Age-dependent regulation of ELP1 exon 20 splicing in Familial Dysautonomia by RNA Polymerase II kinetics and chromatin structure. | PLoS One | 2024 | 38829854 | PubTator, text mining | PubMed |
| Preemptive dual therapy for children at risk for infantile-onset spinal muscular atrophy. | Ann Clin Transl Neurol | 2024 | 38817128 | PubTator, text mining | PubMed |
| Epidemiology of Spinal Muscular Atrophy Based on the Results of a Large-Scale Pilot Project on 202,908 Newborns. | Pediatr Neurol | 2024 | 38781723 | PubTator, text mining | PubMed |
| Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life. | Eur J Paediatr Neurol | 2024 | 38772209 | PubTator, text mining | PubMed |
| Exploring Aromatic Cage Flexibility Using Cosolvent Molecular Dynamics Simulations─An In-Silico Case Study of Tudor Domains. | J Chem Inf Model | 2024 | 38771194 | PubTator, text mining | PubMed |
| Male Reproduction in Spinal Muscular Atrophy (SMA) and the Potential Impact of Oral Survival of Motor Neuron 2 (SMN2) Pre-mRNA Splicing Modifiers. | Neurol Ther | 2024 | 38750391 | PubTator, text mining | PubMed |
| Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment. | Nat Commun | 2024 | 38750052 | PubTator, text mining | PubMed |
| Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide. | Biomed Pharmacother | 2024 | 38749176 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=15